CTI BioPharma (NASDAQ:CTIC) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 3.67 by 3 Brokerage Firm. 2 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.
CTI BioPharma (NASDAQ:CTIC): 2 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $2.88 in CTI BioPharma (NASDAQ:CTIC). However, the stock price could fluctuate by $ 3.01 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $5 price target with the lower price estimate is calculated at $1
CTI BioPharma (NASDAQ:CTIC) witnessed a decline in the market cap on Tuesday as its shares dropped 1.57% or 0.0064 points. After the session commenced at $0.4201, the stock reached the higher end at $0.4255 while it hit a low of $0.4001. With the volume soaring to 967,783 shares, the last trade was called at $0.4001. The company has a 52-week high of $2.29. The company has a market cap of $113 million and there are 282,930,070 shares in outstanding. The 52-week low of the share price is $0.2514.
CTI BioPharma Corp. has lost 4.53% in the last five trading days and dropped 11.87% in the last 4 weeks. CTI BioPharma Corp. has dropped 27.53% during the last 3-month period . Year-to-Date the stock performance stands at -67.47%.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.